A number of clinical trials have demonstrated the efficacy of immunotherapy prior as neoadjuvant therapy. This study evaluates whether said neoadjuvant immunotherapy may improve improve progression free survival in NSCLC. One such example would be to evaluate either single agent or an immunotherapy combination with chemotherapy. Following this, analysis of biomarkers will be conducted to provide personalization in one's regimen.
A number of clinical trials have demonstrated the efficacy of immunotherapy prior as neoadjuvant therapy. This study evaluates whether said neoadjuvant immunotherapy may improve improve progression free survival in NSCLC. \[The Power Life Sciences Investigative Team\](https://www.withpower.com) is running a study to evaluate either single agent or an immunotherapy combination with chemotherapy. Patients can contact a site administrator via the information below, or enroll directly via \<a href="https://www.withpower.com/trial/phase-4-2019-e67c1"\>https://www.withpower.com/trial/phase-4-2019-e67c1\</a\>. Following this, analysis of biomarkers will be conducted to provide personalization in one's regimen.
Study Type
OBSERVATIONAL
Enrollment
10
Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA. Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy.
Power Life Sciences
San Francisco, California, United States
Major Pathological Response
To evaluate the major pathological response (MPR) rate of participants
Time frame: 12 Weeks
Objective Response Rate
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST)
Time frame: 12 Weeks
MPR based on diverse PD-L1 expression
Percentage of Participants with Major Pathologic Response Rates For Programmed Death Ligand 1 (PD-L1)-Positive Versus PD-L1-Negative Participants
Time frame: 12 Weeks
Progression Free Survival
Progression Free Survival (PFS)
Time frame: 12 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.